On GDF-15 neutralisation and cachexia, with CatalYm
Oncology
As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm, a company pioneering GDF-15 neutralisation to address cancer resistance and cachexia.
Clarke discusses updated results from the ongoing Phase 2 GDFATHER-NEO trial of visugromab, a first-in-class anti-GDF-15 antibody, in combination with nivolumab as neoadjuvant treatment for patients with muscle-invasive bladder cancer are scheduled for a rapid oral presentation this weekend.
Watch the conversation and keep on eye on our ESMO 2026 updates here.
